CN102740875A - 基于人血清白蛋白的用于光动力疗法的纳米粒子载体系统 - Google Patents

基于人血清白蛋白的用于光动力疗法的纳米粒子载体系统 Download PDF

Info

Publication number
CN102740875A
CN102740875A CN2010800629189A CN201080062918A CN102740875A CN 102740875 A CN102740875 A CN 102740875A CN 2010800629189 A CN2010800629189 A CN 2010800629189A CN 201080062918 A CN201080062918 A CN 201080062918A CN 102740875 A CN102740875 A CN 102740875A
Authority
CN
China
Prior art keywords
hsa
nanoparticles
nanoparticle
photosensitizer
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800629189A
Other languages
English (en)
Chinese (zh)
Inventor
克劳斯·兰格尔
马蒂亚斯·瓦克尔
比特·罗德
安格莱特·普鲁斯
沃科尔·阿尔布莱奇特
苏珊娜·格拉菲
阿诺·维厄
哈根·冯布里森
西尔维娅·瓦格内
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolitec Investment Ii Co Ltd
Original Assignee
Beletech Pharmaceutical Market Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beletech Pharmaceutical Market Co ltd filed Critical Beletech Pharmaceutical Market Co ltd
Publication of CN102740875A publication Critical patent/CN102740875A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800629189A 2009-12-11 2010-12-08 基于人血清白蛋白的用于光动力疗法的纳米粒子载体系统 Pending CN102740875A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28590209P 2009-12-11 2009-12-11
US61/285,902 2009-12-11
US12/941,350 US9211283B2 (en) 2009-12-11 2010-11-08 Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
US12/941,350 2010-11-08
PCT/US2010/059364 WO2011071968A2 (en) 2009-12-11 2010-12-08 Nanoparticle carrier systems based on human serum albumin for photodynamic therapy

Publications (1)

Publication Number Publication Date
CN102740875A true CN102740875A (zh) 2012-10-17

Family

ID=44143223

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800629189A Pending CN102740875A (zh) 2009-12-11 2010-12-08 基于人血清白蛋白的用于光动力疗法的纳米粒子载体系统

Country Status (7)

Country Link
US (1) US9211283B2 (https=)
EP (1) EP2509620A4 (https=)
JP (1) JP5972171B2 (https=)
CN (1) CN102740875A (https=)
BR (1) BR112012013952A2 (https=)
CA (1) CA2784001C (https=)
WO (1) WO2011071968A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103169968A (zh) * 2013-03-12 2013-06-26 中国科学院理化技术研究所 一种基于白蛋白的疏水二氢卟吩光敏剂纳米药物制剂、制备方法及其应用
CN104587466A (zh) * 2014-12-15 2015-05-06 苏州大学 蛋白-聚吡咯复合物及蛋白-聚吡咯复合物衍生物的制备方法与应用
CN105283174A (zh) * 2013-05-02 2016-01-27 株式会社Jinis 靶向增强的抗癌纳米颗粒及其制备方法
CN113855645A (zh) * 2021-09-13 2021-12-31 苏州大学 一种基于功能化蛋白质纳米粒的核壳型组装体及其制备方法与应用
WO2023039691A1 (zh) * 2021-09-17 2023-03-23 苏州大学 一种基于功能化蛋白质纳米粒的核壳型组装体及其制备方法与应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2591803A1 (de) * 2011-11-09 2013-05-15 APOCARE Pharma GmbH Zusammensetzung für die photodynamische Diagnostik und Therapie von Tumoren
EP3201201B1 (en) 2014-09-30 2022-01-26 biolitec unternehmensbeteiligungs II AG Specifically meso-substituted porphyrins and chlorins for photodynamic therapy
ES3011714T3 (en) 2016-02-26 2025-04-08 Biolitec Holding Gmbh & Co Kg Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy
DE102016125666A1 (de) * 2016-12-23 2018-06-28 Michael Denck HSA-Galenik
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥方法
WO2020120474A1 (en) 2018-12-10 2020-06-18 Universität Hamburg Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy
CN113614477B (zh) 2019-03-14 2023-04-28 泰尔茂比司特生物技术有限公司 冷冻干燥装载托盘组件及系统
CN110251672B (zh) * 2019-06-18 2022-04-01 深圳大学 一种纳米诊疗剂及其制备方法与应用
CN111110861B (zh) * 2020-02-23 2023-08-25 上海交通大学医学院附属瑞金医院 一种基于人血清白蛋白的载药颗粒及其制备方法
CN112972676B (zh) * 2020-08-17 2024-09-24 滨州医学院 HSA-Biotin-DDA-TCPP分子的合成及其作为光动力治疗剂及纳米药的应用
WO2022074014A1 (en) * 2020-10-05 2022-04-14 Biolitec Unternehmensbeteiligungs Ii Ag Tetrapyrrole-based compounds and their formulations for anti-microbial therapy
CA3231406A1 (en) * 2021-09-17 2023-03-23 Huang-chiao HUANG Amorphous photosensitizing particles, methods for the preparation thereof, and methods for the use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007791A (en) * 1994-10-10 1999-12-28 Chiron Corporation Preparation of protein microspheres, films and coatings
US20040047913A1 (en) * 2002-05-16 2004-03-11 Eric Allemann Compositions and methods for delivery of photosensitive drugs
US20070218049A1 (en) * 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same
US20100278303A1 (en) * 2009-04-30 2010-11-04 Lee Grodzins Localization of an Element of Interest by XRF Analysis of Different Inspection Volumes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8805849D0 (en) 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5648485A (en) 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US6649192B2 (en) * 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
WO2000061584A1 (en) 1999-04-14 2000-10-19 The University Of British Columbia IMPROVED β,β,-DIHYDROXY MESO-SUBSTITUTED CHLORINS, ISOBACTERIOCHLORINS, AND BACTERIOCHLORINS
DE60032372T2 (de) 1999-09-23 2007-10-11 Dabur Pharma Ltd., New Delhi Arzneizubereitungen enthaltend paclitaxel eingeschlossen in nanopartikeln von polymerischen mizellen
US20030103995A1 (en) * 2001-06-04 2003-06-05 Hamblin Michael R. Detection and therapy of vulnerable plaque with photodynamic compounds
US8709449B2 (en) * 2004-02-12 2014-04-29 Biolitec Pharma Marketing Ltd Methods and compositions for improving photodynamic therapy through administration of lipids
DE102004011776A1 (de) * 2004-03-09 2005-11-03 Lts Lohmann Therapie-Systeme Ag Trägersystem in Form von Nanopartikeln auf Proteinbasis zur zellspezifischen Anreicherung von pharmazeutisch aktiven Wirkstoffen
JP2006056807A (ja) * 2004-08-18 2006-03-02 Konica Minolta Medical & Graphic Inc 光線力学療法製剤
WO2006133271A2 (en) * 2005-06-06 2006-12-14 The General Hospital Corporation Compositions and methods relating to target-specific photodynamic therapy
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
JP2011517683A (ja) * 2008-04-10 2011-06-16 アブラクシス バイオサイエンス， エルエルシー 疎水性タキサン誘導体の組成物およびその使用
US8815931B2 (en) * 2009-04-28 2014-08-26 Biolitec Pharma Marketing Ltd Oral formulations for tetrapyrrole derivatives
US20110275686A1 (en) * 2009-12-11 2011-11-10 Biolitec, Inc. Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6007791A (en) * 1994-10-10 1999-12-28 Chiron Corporation Preparation of protein microspheres, films and coatings
US20040047913A1 (en) * 2002-05-16 2004-03-11 Eric Allemann Compositions and methods for delivery of photosensitive drugs
US20070218049A1 (en) * 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same
US20100278303A1 (en) * 2009-04-30 2010-11-04 Lee Grodzins Localization of an Element of Interest by XRF Analysis of Different Inspection Volumes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHIARA COMPAGNIN ET AL: "The cellular uptake of meta-tetra(hydroxyphenly)chlorine entrapped in organically modified silica nanoparticles is mediated by serum proteins", 《NANOTECHNOLOGY》, vol. 20, 26 August 2009 (2009-08-26) *
KUAN CHEN ET AL: "Novel photosensitizer-protein nanoparticles for photodynamic therapy:photophsical characterization and in vitro investigations", 《JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B:BIOLOGY》, vol. 96, 2 April 2009 (2009-04-02), pages 67 - 70 *
VNGELICE ET AL: "Toward the understanding of the photodynamic activity of m-THPP encapsulated in PLGA nanopartic correlation between nanoparticle properties and in vivo activity", 《JOURNAL OF DRUG TARGETING》, vol. 17, no. 8, 10 July 2009 (2009-07-10), pages 600 - 1 *
吴云霞等: "血卟啉衍生物与人血清白蛋白作用的光谱特性研究", 《光谱学与光谱分析》, vol. 25, no. 10, 30 October 2005 (2005-10-30) *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103169968A (zh) * 2013-03-12 2013-06-26 中国科学院理化技术研究所 一种基于白蛋白的疏水二氢卟吩光敏剂纳米药物制剂、制备方法及其应用
CN103169968B (zh) * 2013-03-12 2014-11-26 中国科学院理化技术研究所 一种基于白蛋白的疏水二氢卟吩光敏剂纳米药物制剂、制备方法及其应用
CN105283174A (zh) * 2013-05-02 2016-01-27 株式会社Jinis 靶向增强的抗癌纳米颗粒及其制备方法
CN105283174B (zh) * 2013-05-02 2019-09-24 株式会社Jinis 靶向增强的抗癌纳米颗粒及其制备方法
CN104587466A (zh) * 2014-12-15 2015-05-06 苏州大学 蛋白-聚吡咯复合物及蛋白-聚吡咯复合物衍生物的制备方法与应用
CN104587466B (zh) * 2014-12-15 2017-11-21 苏州大学 蛋白‑聚吡咯复合物及蛋白‑聚吡咯复合物衍生物的制备方法与应用
CN113855645A (zh) * 2021-09-13 2021-12-31 苏州大学 一种基于功能化蛋白质纳米粒的核壳型组装体及其制备方法与应用
CN113855645B (zh) * 2021-09-13 2024-02-02 苏州大学 一种基于功能化蛋白质纳米粒的核壳型组装体及其制备方法与应用
WO2023039691A1 (zh) * 2021-09-17 2023-03-23 苏州大学 一种基于功能化蛋白质纳米粒的核壳型组装体及其制备方法与应用

Also Published As

Publication number Publication date
BR112012013952A2 (en) 2018-06-05
WO2011071968A2 (en) 2011-06-16
US9211283B2 (en) 2015-12-15
JP2013513609A (ja) 2013-04-22
EP2509620A4 (en) 2015-10-21
WO2011071968A3 (en) 2011-11-17
JP5972171B2 (ja) 2016-08-17
EP2509620A2 (en) 2012-10-17
CA2784001C (en) 2018-04-10
US20110142948A1 (en) 2011-06-16
CA2784001A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
CN102740875A (zh) 基于人血清白蛋白的用于光动力疗法的纳米粒子载体系统
JP5868869B2 (ja) 光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム
Camerin et al. The in vivo efficacy of phthalocyanine–nanoparticle conjugates for the photodynamic therapy of amelanotic melanoma
Lee et al. Tumor-homing photosensitizer-conjugated glycol chitosan nanoparticles for synchronous photodynamic imaging and therapy based on cellular on/off system
AU2004207813B2 (en) Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles
Wang et al. Multifunctional biodegradable polyacrylamide nanocarriers for cancer theranostics A “see and treat” strategy
KR102081666B1 (ko) 암 치료용 약학 조성물
Wacker et al. Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties
Geng et al. NIR-triggered ligand-presenting nanocarriers for enhancing synergistic photothermal-chemotherapy
KR20110101338A (ko) 광역학 진단 또는 치료를 위한 생체 적합성 고분자와 광감작제의 결합체 및 이의 제조방법
de Toledo et al. Zinc phthalocyanine tetrasulfonate-loaded polyelectrolytic PLGA nanoparticles for photodynamic therapy applications
CN101524326A (zh) 一种二氢卟吩e6壳聚糖-硬脂酸嫁接物胶束
KR102525384B1 (ko) 이중 약물이 봉입된 세포외 소포체의 제조방법
da Silva et al. In vitro photodynamic activity of chloro (5, 10, 15, 20-tetraphenylporphyrinato) indium (III) loaded-poly (lactide-co-glycolide) nanoparticles in LNCaP prostate tumour cells
CN113827553B (zh) 用于肿瘤光动力学治疗的瘤内注射给药的酞菁锌在位凝胶及其制备方法
CN1565433A (zh) 竹红菌素水溶性纳米粒及用途
Shabbirahmed et al. Recent advancements in nanomaterials for photodynamic therapy of cancers
US11040101B2 (en) Nanoparticles for cancer therapy and diagnosis
Pietkiewicz et al. In vitro studies of serum albumin interaction with poly (D, L-lactide) nanospheres loaded by hydrophobic cargo
CN103933568A (zh) 一种水溶性竹红菌素plga纳米粒及其制备方法
CN119591669A (zh) 一种肿瘤微环境pH响应型尺寸可变的肽自组装药物载体及其在肿瘤特异性治疗中的应用
Urszula In vitro studies of serum albumin interaction with
Gu Biodegradable porous silicon nanomaterials for imaging and treatment of cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160310

Address after: Austria Vienna

Applicant after: BIOLITEC INVESTMENT II CO., LTD.

Address before: Malaysia rabouin

Applicant before: Biolitec Pharma Marketing Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20121017